pharmaphorum

DECEMBER 29, 2021

IL-13 inhibitor tralokinumab has been cleared by the US regulator as Adbry as a treatment for moderate-to-severe atopic dermatitis in adults who can’t control symptoms using topical prescription therapies.

Sales 111

Sales Dermatology Marketing Allergies 111

Scienmag

MAY 21, 2021

UC San Diego School of Medicine researchers identify how the body regulates and prevents constant skin inflammation The human body is constantly exposed to various environmental actors, from viruses to bacteria to fungi, but most of these microbial organisms provoke little or no response from our skin, which is charged with monitoring and protecting (..)

Bacteria 75

Bacteria Regulation Medicine Research 75

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

AUGUST 2, 2023

In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. The TPO receptor agonist regulates blood platelet production by binding to and activating TPO receptors on megakaryocyte cells and inducing signalling cascades that increase platelet production.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 24, 2024

Xolair, Caregiver As part of Novartis and Genentechs national campaign Accidents Happen, Caregiver is one of two ads for the companies asthma and allergy drug Xolair (omalizumab). The ad highlights the care parents take in managing their childrens food allergies while acknowledging the risk of accidental exposure.

Drugs 105

Drugs Allergies Vaccination Vaccine 105